SEC Tracker
Get the app

Xilio Therapeutics XLO

Xilio Development, Inc., a wholly-owned subsidiary of Xilio Therapeutics, Inc.

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Reports quarterly results (2.02)
  • Announces exit or restructuring costs (2.05)
  • Sells unregistered shares (3.02)
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Xilio Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  2. Annovis Bio ANVS public float $36M, Jun 30, 2025
  3. Kezar Life Sciences KZR public float $33M, Jun 30, 2025
  4. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  5. Karyopharm Therapeutics KPTI public float $37M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.